MYGN
Myriad Genetics, Inc.
Price Chart
Latest Quote
$4.63
+0.13 (+2.89%)
Current Price
| Previous Close | $4.50 |
| Open | $4.41 |
| Day High | $4.71 |
| Day Low | $4.39 |
| Volume | 1,261,125 |
Stock Information
| Shares Outstanding | 94.45M |
| Cash Equivalents | $150.70M |
| Revenue | $557.00M |
| Net Income | $-230.00M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $437.30M |
| EPS (TTM) | $-4.31 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $286.60M |
| Sales | $557.00M |
| Income | $-230.00M |
| Book/sh | $3.57 |
| Cash/sh | $1.60 |
| Employees | 3K |
Financial Ratios
| Quick Ratio | 1.65 |
| Current Ratio | 2.67 |
| Debt/Eq | 32.84 |
Returns & Margins
| ROA | -7.65% |
| ROE | -23.51% |
| Gross Margin | 68.06% |
| Operating Margin | -21.41% |
| Profit Margin | -41.29% |
Ownership
| Insider Ownership | 3.78% |
| Institutional Ownership | 97.37% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 30.64 |
| PEG | 1.24 |
| P/S | 0.79 |
| P/B | 1.30 |
Analyst Data
| Recommendation | none |
| Target Price | $6.25 |
Technical Indicators
| SMA20 | $4.36 |
| SMA50 | $4.42 |
| SMA200 | $5.84 |
| RSI | 58.08 |
| ATR | 0.2893 |
| Shares Float | 85.99M |
| Short Float | 9.28% |
| Short Ratio | 4.19 |
| Volatility | 1.64 |
| Rel Volume | 0.75 |
Performance History
| Week | +7.18% |
| Month | +18.41% |
| Quarter | -0.64% |
| 6 Months | -30.90% |
| YTD | -24.59% |
| Year | -5.89% |
| 3 Years | -79.82% |
| 5 Years | -84.55% |
| 10 Years | -84.57% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $4.63 | 1,271,900 |
| 2026-06-22 | $4.50 | 1,271,200 |
| 2026-06-18 | $4.54 | 2,436,300 |
| 2026-06-17 | $4.38 | 876,800 |
| 2026-06-16 | $4.25 | 1,273,700 |
| 2026-06-15 | $4.32 | 1,128,300 |
| 2026-06-12 | $4.33 | 1,192,400 |
| 2026-06-11 | $4.63 | 1,711,900 |
| 2026-06-10 | $4.43 | 1,444,900 |
| 2026-06-09 | $4.54 | 1,137,900 |
| 2026-06-08 | $4.39 | 973,900 |
| 2026-06-05 | $4.57 | 1,153,300 |
| 2026-06-04 | $4.69 | 1,638,800 |
| 2026-06-03 | $4.40 | 1,982,500 |
| 2026-06-02 | $4.31 | 2,380,600 |
| 2026-06-01 | $4.28 | 2,066,000 |
| 2026-05-29 | $3.97 | 6,042,000 |
| 2026-05-28 | $4.22 | 1,848,900 |
| 2026-05-27 | $3.93 | 866,000 |
| 2026-05-26 | $3.85 | 1,020,700 |
About Myriad Genetics, Inc.
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
đ° Latest News
Should You Add Myriad Genetics Stock to Your Portfolio Right Now?
Zacks âĸ 2026-06-09T14:01:00Z
1 Cash-Burning Stock with Promising Prospects and 2 Facing Headwinds
StockStory âĸ 2026-06-05T13:12:14Z
3 High-Flying Stocks Weâre Skeptical Of
StockStory âĸ 2026-06-04T20:45:30Z
Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?
Zacks âĸ 2026-06-04T15:30:22Z
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
Zacks âĸ 2026-06-02T16:09:00Z
Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock
Zacks âĸ 2026-05-28T13:24:00Z
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh
Zacks âĸ 2026-05-28T13:20:00Z
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans
Zacks âĸ 2026-05-27T12:48:00Z
1 Unprofitable Stock to Consider Right Now and 2 We Turn Down
StockStory âĸ 2026-05-23T09:00:55Z
Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN)
Zacks âĸ 2026-05-18T13:35:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $247,900,000 | $252,200,000 | $236,200,000 | $202,000,000 |
| Cost Of Revenue | $247,900,000 | $252,200,000 | $236,200,000 | $202,000,000 |
| Total Revenue | $824,500,000 | $837,600,000 | $753,200,000 | $678,400,000 |
| Operating Revenue | $824,500,000 | $837,600,000 | $753,200,000 | $678,400,000 |
| Expenses | ||||
| Interest Expense | $10,500,000 | $2,800,000 | $2,900,000 | $3,200,000 |
| Total Expenses | $892,300,000 | $925,600,000 | $897,800,000 | $802,100,000 |
| Other Income Expense | $-318,600,000 | $-34,400,000 | $-117,200,000 | $-16,300,000 |
| Other Non Operating Income Expenses | $800,000 | $1,100,000 | $-4,400,000 | $600,000 |
| Net Non Operating Interest Income Expense | $-8,700,000 | $-1,100,000 | $-400,000 | $-600,000 |
| Interest Expense Non Operating | $10,500,000 | $2,800,000 | $2,900,000 | $3,200,000 |
| Operating Expense | $644,400,000 | $673,400,000 | $661,600,000 | $600,100,000 |
| Selling And Marketing Expense | $280,800,000 | $284,100,000 | $289,200,000 | $266,800,000 |
| General And Administrative Expense | $256,800,000 | $275,900,000 | $283,700,000 | $247,900,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-365,900,000 | $-127,300,000 | $-263,300,000 | $-112,000,000 |
| Net Interest Income | $-8,700,000 | $-1,100,000 | $-400,000 | $-600,000 |
| Interest Income | $1,800,000 | $1,700,000 | $2,500,000 | $2,600,000 |
| Normalized Income | $-70,135,600 | $-99,255,000 | $-174,188,000 | $-98,537,696 |
| Net Income From Continuing And Discontinued Operation | $-365,900,000 | $-127,300,000 | $-263,300,000 | $-112,000,000 |
| Total Operating Income As Reported | $-387,200,000 | $-123,500,000 | $-257,400,000 | $-140,600,000 |
| Net Income Common Stockholders | $-365,900,000 | $-127,300,000 | $-263,300,000 | $-112,000,000 |
| Net Income | $-365,900,000 | $-127,300,000 | $-263,300,000 | $-112,000,000 |
| Net Income Including Noncontrolling Interests | $-365,900,000 | $-127,300,000 | $-263,300,000 | $-112,000,000 |
| Net Income Continuous Operations | $-365,900,000 | $-127,300,000 | $-263,300,000 | $-112,000,000 |
| Pretax Income | $-395,100,000 | $-123,500,000 | $-262,200,000 | $-140,600,000 |
| Special Income Charges | $-319,400,000 | $-35,500,000 | $-112,800,000 | $-16,900,000 |
| Interest Income Non Operating | $1,800,000 | $1,700,000 | $2,500,000 | $2,600,000 |
| Operating Income | $-67,800,000 | $-88,000,000 | $-144,600,000 | $-123,700,000 |
| Gross Profit | $576,600,000 | $585,400,000 | $517,000,000 | $476,400,000 |
| Per Share | ||||
| Diluted EPS | $-3.95 | $-1.41 | $-3.18 | $-1.39 |
| Basic EPS | $-3.95 | $-1.41 | $-3.18 | $-1.39 |
| Other | ||||
| Tax Effect Of Unusual Items | $-23,635,600 | $-7,455,000 | $-23,688,000 | $-3,437,696 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,500,000 | $-24,000,000 | $-84,600,000 | $-67,800,000 |
| Total Unusual Items | $-319,400,000 | $-35,500,000 | $-112,800,000 | $-16,900,000 |
| Total Unusual Items Excluding Goodwill | $-319,400,000 | $-35,500,000 | $-112,800,000 | $-16,900,000 |
| Reconciled Depreciation | $53,700,000 | $61,200,000 | $61,900,000 | $52,700,000 |
| EBITDA (Bullshit earnings) | $-330,900,000 | $-59,500,000 | $-197,400,000 | $-84,700,000 |
| EBIT | $-384,600,000 | $-120,700,000 | $-259,300,000 | $-137,400,000 |
| Diluted Average Shares | $92,600,000 | $90,600,000 | $82,800,000 | $80,600,000 |
| Basic Average Shares | $92,600,000 | $90,600,000 | $82,800,000 | $80,600,000 |
| Diluted NI Availto Com Stockholders | $-365,900,000 | $-127,300,000 | $-263,300,000 | $-112,000,000 |
| Tax Provision | $-29,200,000 | $3,800,000 | $1,100,000 | $-28,600,000 |
| Impairment Of Capital Assets | $319,400,000 | $56,800,000 | $0 | $16,900,000 |
| Research And Development | $106,800,000 | $113,400,000 | $88,700,000 | $85,400,000 |
| Selling General And Administration | $537,600,000 | $560,000,000 | $572,900,000 | $514,700,000 |
| Other Gand A | $256,800,000 | $275,900,000 | $283,700,000 | $247,900,000 |
| Other Special Charges | - | $-21,300,000 | $112,800,000 | - |
| Minority Interests | - | - | - | $0 |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $163,000,000 | $152,400,000 | $146,300,000 | $219,300,000 |
| Total Assets | $706,600,000 | $1,027,600,000 | $1,146,500,000 | $1,198,700,000 |
| Total Non Current Assets | $374,000,000 | $729,600,000 | $832,900,000 | $924,100,000 |
| Other Non Current Assets | $5,600,000 | $8,500,000 | $15,400,000 | $15,500,000 |
| Goodwill And Other Intangible Assets | $205,000,000 | $548,700,000 | $636,900,000 | $666,500,000 |
| Other Intangible Assets | $153,400,000 | $262,400,000 | $349,500,000 | $379,700,000 |
| Current Assets | $332,600,000 | $298,000,000 | $313,600,000 | $274,600,000 |
| Other Current Assets | $25,100,000 | $30,500,000 | $19,400,000 | $20,400,000 |
| Prepaid Assets | $12,000,000 | $16,400,000 | $17,000,000 | $17,600,000 |
| Inventory | $30,600,000 | $27,500,000 | $22,000,000 | $20,100,000 |
| Receivables | $115,300,000 | $121,200,000 | $114,300,000 | $101,600,000 |
| Accounts Receivable | $115,300,000 | $121,200,000 | $114,300,000 | $101,600,000 |
| Cash Cash Equivalents And Short Term Investments | $149,600,000 | $102,400,000 | $140,900,000 | $114,900,000 |
| Cash And Cash Equivalents | $149,600,000 | $102,400,000 | $132,100,000 | $56,900,000 |
| Investmentin Financial Assets | - | - | $0 | $54,800,000 |
| Cash Equivalents | - | - | $2,200,000 | $3,300,000 |
| Cash Financial | - | - | $129,900,000 | $53,600,000 |
| Debt | ||||
| Total Debt | $209,800,000 | $140,300,000 | $152,100,000 | $145,000,000 |
| Long Term Debt And Capital Lease Obligation | $202,900,000 | $127,500,000 | $135,900,000 | $130,900,000 |
| Long Term Debt | $119,900,000 | $39,600,000 | $38,500,000 | - |
| Current Debt And Capital Lease Obligation | $6,900,000 | $12,800,000 | $16,200,000 | $14,100,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $338,600,000 | $326,500,000 | $363,300,000 | $312,900,000 |
| Total Non Current Liabilities Net Minority Interest | $204,800,000 | $162,400,000 | $207,400,000 | $175,700,000 |
| Other Non Current Liabilities | $1,700,000 | $2,200,000 | $41,300,000 | $18,000,000 |
| Tradeand Other Payables Non Current | $200,000 | $32,700,000 | $30,200,000 | $26,800,000 |
| Current Liabilities | $133,800,000 | $164,100,000 | $155,900,000 | $137,200,000 |
| Payables And Accrued Expenses | $75,700,000 | $86,400,000 | $90,000,000 | $81,900,000 |
| Payables | $55,600,000 | $57,300,000 | $50,500,000 | $52,900,000 |
| Other Payable | $19,900,000 | $19,900,000 | $20,100,000 | $19,300,000 |
| Total Tax Payable | $5,700,000 | $5,100,000 | $4,600,000 | $4,800,000 |
| Accounts Payable | $30,000,000 | $32,300,000 | $25,800,000 | $28,800,000 |
| Other Current Liabilities | - | $7,500,000 | $10,400,000 | - |
| Non Current Deferred Liabilities | - | - | - | $3,500,000 |
| Non Current Deferred Taxes Liabilities | - | - | - | $3,500,000 |
| Current Deferred Liabilities | - | - | - | $600,000 |
| Equity | ||||
| Common Stock Equity | $368,000,000 | $701,100,000 | $783,200,000 | $885,800,000 |
| Total Equity Gross Minority Interest | $368,000,000 | $701,100,000 | $783,200,000 | $885,800,000 |
| Stockholders Equity | $368,000,000 | $701,100,000 | $783,200,000 | $885,800,000 |
| Gains Losses Not Affecting Retained Earnings | $800,000 | $-800,000 | $-3,700,000 | $-8,900,000 |
| Other Equity Adjustments | $800,000 | $-800,000 | $-3,700,000 | $-8,900,000 |
| Retained Earnings | $-1,122,700,000 | $-756,800,000 | $-629,500,000 | $-366,200,000 |
| Other | ||||
| Ordinary Shares Number | $93,500,000 | $91,300,000 | $89,900,000 | $81,200,000 |
| Share Issued | $93,500,000 | $91,300,000 | $89,900,000 | $81,200,000 |
| Tangible Book Value | $163,000,000 | $152,400,000 | $146,300,000 | $219,300,000 |
| Invested Capital | $487,900,000 | $740,700,000 | $821,700,000 | $885,800,000 |
| Working Capital | $198,800,000 | $133,900,000 | $157,700,000 | $137,400,000 |
| Capital Lease Obligations | $89,900,000 | $100,700,000 | $113,600,000 | $145,000,000 |
| Total Capitalization | $487,900,000 | $740,700,000 | $821,700,000 | $885,800,000 |
| Additional Paid In Capital | $1,489,000,000 | $1,457,800,000 | $1,415,500,000 | $1,260,100,000 |
| Capital Stock | $900,000 | $900,000 | $900,000 | $800,000 |
| Common Stock | $900,000 | $900,000 | $900,000 | $800,000 |
| Long Term Capital Lease Obligation | $83,000,000 | $87,900,000 | $97,400,000 | $130,900,000 |
| Current Capital Lease Obligation | $6,900,000 | $12,800,000 | $16,200,000 | $14,100,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $51,200,000 | $57,400,000 | $49,700,000 | $41,200,000 |
| Current Accrued Expenses | $20,100,000 | $29,100,000 | $39,500,000 | $29,000,000 |
| Goodwill | $51,600,000 | $286,300,000 | $287,400,000 | $286,800,000 |
| Net PPE | $163,400,000 | $172,400,000 | $180,600,000 | $187,300,000 |
| Accumulated Depreciation | $-87,900,000 | $-109,600,000 | $-119,900,000 | $-109,200,000 |
| Gross PPE | $251,300,000 | $282,000,000 | $300,500,000 | $296,500,000 |
| Leases | $80,400,000 | $78,500,000 | $91,300,000 | $67,900,000 |
| Other Properties | $170,900,000 | $203,500,000 | $209,200,000 | $228,600,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | - | $0 | $8,800,000 | $58,000,000 |
| Investments And Advances | - | - | $0 | $54,800,000 |
| Machinery Furniture Equipment | - | - | $147,600,000 | $124,700,000 |
| Minority Interest | - | - | - | $0 |
| Current Deferred Revenue | - | - | - | $600,000 |
| Available For Sale Securities | - | - | - | $54,800,000 |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-25,600,000 | $-38,400,000 | $-184,200,000 | $-151,600,000 |
| Operating Activities | ||||
| Operating Cash Flow | $1,800,000 | $-8,700,000 | $-110,900,000 | $-106,300,000 |
| Cash Flow From Continuing Operating Activities | $1,800,000 | $-8,700,000 | $-110,900,000 | $-106,300,000 |
| Operating Gains Losses | - | - | $1,500,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-27,400,000 | $-29,700,000 | $-73,300,000 | $-45,300,000 |
| Investing Cash Flow | $-27,400,000 | $-11,900,000 | $31,900,000 | $-77,500,000 |
| Cash Flow From Continuing Investing Activities | $-27,400,000 | $-11,900,000 | $31,900,000 | $-77,500,000 |
| Capital Expenditure Reported | $-27,400,000 | $-29,700,000 | $-73,300,000 | $-45,300,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $0 | $117,600,000 | $0 |
| Financing Cash Flow | $64,200,000 | $-7,400,000 | $152,900,000 | $-8,000,000 |
| Cash Flow From Continuing Financing Activities | $64,200,000 | $-7,400,000 | $152,900,000 | $-8,000,000 |
| Net Other Financing Charges | $-23,400,000 | $-13,400,000 | $-10,500,000 | $-14,300,000 |
| Net Common Stock Issuance | $0 | $0 | $117,600,000 | $0 |
| Common Stock Issuance | $0 | $0 | $117,600,000 | $0 |
| Repurchase Of Capital Stock | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-80,700,000 | $-119,900,000 | $-40,200,000 | $0 |
| Issuance Of Debt | $165,000,000 | $120,000,000 | $80,000,000 | $0 |
| Interest Paid Supplemental Data | $8,400,000 | $1,900,000 | $1,400,000 | $0 |
| End Cash Position | $151,300,000 | $111,900,000 | $140,900,000 | $66,400,000 |
| Beginning Cash Position | $111,900,000 | $140,900,000 | $66,400,000 | $258,800,000 |
| Effect Of Exchange Rate Changes | $800,000 | $-1,000,000 | $600,000 | $-600,000 |
| Changes In Cash | $38,600,000 | $-28,000,000 | $73,900,000 | $-191,800,000 |
| Proceeds From Stock Option Exercised | $3,300,000 | $5,900,000 | $6,000,000 | $6,300,000 |
| Net Issuance Payments Of Debt | $84,300,000 | $100,000 | $39,800,000 | $0 |
| Net Long Term Debt Issuance | $84,300,000 | $100,000 | $39,800,000 | $0 |
| Long Term Debt Payments | $-80,700,000 | $-119,900,000 | $-40,200,000 | $0 |
| Long Term Debt Issuance | $165,000,000 | $120,000,000 | $80,000,000 | $0 |
| Net Investment Purchase And Sale | $0 | $9,000,000 | $105,200,000 | $25,000,000 |
| Sale Of Investment | $0 | $9,000,000 | $105,200,000 | $128,200,000 |
| Net Business Purchase And Sale | $0 | $8,800,000 | $0 | $-57,200,000 |
| Sale Of Business | $0 | $8,800,000 | $0 | $0 |
| Change In Working Capital | $-19,300,000 | $-54,400,000 | $10,700,000 | $-101,500,000 |
| Change In Other Current Assets | $2,000,000 | $0 | $600,000 | $-900,000 |
| Change In Payables And Accrued Expense | $-28,900,000 | $-36,300,000 | $23,500,000 | $-89,700,000 |
| Change In Accrued Expense | $-27,500,000 | $-41,000,000 | $27,200,000 | $-86,200,000 |
| Change In Payable | $-1,400,000 | $4,700,000 | $-3,700,000 | $-3,500,000 |
| Change In Account Payable | $-1,400,000 | $4,700,000 | $-3,700,000 | $-3,500,000 |
| Change In Prepaid Assets | $4,600,000 | $-3,200,000 | $900,000 | $2,300,000 |
| Change In Inventory | $-3,200,000 | $-6,200,000 | $-1,800,000 | $-2,900,000 |
| Change In Receivables | $6,200,000 | $-8,700,000 | $-12,500,000 | $-10,300,000 |
| Changes In Account Receivables | $6,200,000 | $-8,700,000 | $-12,500,000 | $-10,300,000 |
| Other Non Cash Items | $11,100,000 | $5,700,000 | $39,700,000 | $31,400,000 |
| Stock Based Compensation | $35,200,000 | $49,800,000 | $40,700,000 | $38,100,000 |
| Asset Impairment Charge | $319,400,000 | $56,600,000 | $0 | $16,900,000 |
| Deferred Tax | $-32,400,000 | $-300,000 | $-600,000 | $-31,900,000 |
| Deferred Income Tax | $-32,400,000 | $-300,000 | $-600,000 | $-31,900,000 |
| Depreciation Amortization Depletion | $53,700,000 | $61,200,000 | $61,900,000 | $52,700,000 |
| Depreciation And Amortization | $53,700,000 | $61,200,000 | $61,900,000 | $52,700,000 |
| Net Income From Continuing Operations | $-365,900,000 | $-127,300,000 | $-263,300,000 | $-112,000,000 |
| Income Tax Paid Supplemental Data | - | $2,700,000 | $1,900,000 | $1,800,000 |
| Purchase Of Investment | - | $0 | $0 | $-103,200,000 |
| Purchase Of Business | - | $0 | $0 | $-57,200,000 |
| Change In Other Working Capital | - | - | $-200,000 | $-5,000,000 |
| Gain Loss On Investment Securities | - | - | $1,500,000 | - |
| Gain Loss On Sale Of Business | - | - | $0 | $0 |
| Net Foreign Currency Exchange Gain Loss | - | - | - | $0 |
| Common Stock Payments | - | - | - | - |
| Net Short Term Debt Issuance | - | - | - | - |
| Short Term Debt Payments | - | - | - | - |
| Short Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-15